<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux) in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) </plain></SENT>
<SENT sid="1" pm="."><plain>This study sought to determine if KRAS mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> lines could be sensitized to cetuximab using <z:chebi fb="0" ids="49375">dasatinib</z:chebi> (BMS-354825, Sprycel), a potent, orally bioavailable inhibitor of several tyrosine kinases, including the Src family kinases (SFKs) </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed 16 CRC lines for: (1) KRAS mutation status, (2) dependence on mutant KRAS signaling and (3) expression level of epidermal growth factor receptor (EGFR) and SFKs </plain></SENT>
<SENT sid="3" pm="."><plain>From these analyses, we selected three KRAS mutant (LS180, LoVo and HCT116) cell lines and two KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> cell lines (SW48 and CaCo2) </plain></SENT>
<SENT sid="4" pm="."><plain>In vitro, using poly-<z:chebi fb="0" ids="16855">D-lysine</z:chebi>/laminin plates, KRAS mutant cell lines were resistant to cetuximab, whereas KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> lines showed sensitivity to cetuximab </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with cetuximab and <z:chebi fb="0" ids="49375">dasatinib</z:chebi> showed a greater antiproliferative effect on KRAS mutant lines when compared with either agent alone in vitro and in vivo </plain></SENT>
<SENT sid="6" pm="."><plain>To investigate potential mechanisms for this antiproliferative response in the combinatorial therapy, we performed Human Phospho-Kinase Antibody Array analysis, measuring the relative phosphorylation levels of 39 intracellular proteins in untreated, cetuximab, <z:chebi fb="0" ids="49375">dasatinib</z:chebi> or the combinatorial treatment in the KRAS mutant lines LS180, LoVo and HCT116 cells </plain></SENT>
<SENT sid="7" pm="."><plain>The results of this experiment showed a decrease in a broad spectrum of kinases centered on the Î²-catenin pathway, the <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK) pathway, AKT/mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR) pathway and the family of signal transducers and activators of transcription (STATs) when compared with the untreated control or monotherapy treatments </plain></SENT>
<SENT sid="8" pm="."><plain>Next, we analyzed <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> with cetuximab, <z:chebi fb="0" ids="49375">dasatinib</z:chebi> or their combination in vivo </plain></SENT>
<SENT sid="9" pm="."><plain>KRAS mutant xenografts showed resistance to cetuximab therapy, whereas KRAS <z:mp ids='MP_0002169'>wild type</z:mp> demonstrated an antitumor response when treated with cetuximab </plain></SENT>
<SENT sid="10" pm="."><plain>KRAS mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> exhibited minimal response to <z:chebi fb="0" ids="49375">dasatinib</z:chebi> monotherapy </plain></SENT>
<SENT sid="11" pm="."><plain>However, as in vitro, KRAS mutant lines exhibited a response to the combination of cetuximab and <z:chebi fb="0" ids="49375">dasatinib</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Combinatorial treatment of KRAS mutant xenografts resulted in <z:mp ids='MP_0000352'>decreased cell proliferation</z:mp>, as measured by Ki67, and higher rates of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, as measured by TUNEL (terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick end labeling) </plain></SENT>
<SENT sid="13" pm="."><plain>The data presented in this study indicate that <z:chebi fb="0" ids="49375">dasatinib</z:chebi> can sensitize KRAS mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> to cetuximab and may do so by altering the activity of several key signaling pathways </plain></SENT>
<SENT sid="14" pm="."><plain>Furthermore, these results suggest that signaling via EGFR and SFKs may be necessary for cell proliferation and survival of KRAS mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>These data strengthen the rationale for clinical trials combining cetuximab and <z:chebi fb="0" ids="49375">dasatinib</z:chebi> in the KRAS mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> genetic setting </plain></SENT>
</text></document>